Legend Biotech Wins FDA IND Clearance for First Dual-Targeting In Vivo CAR-T (LB2501)
LEGN sits 18% above its 52-week low of $16.24.
Summary
Legend Biotech received FDA IND clearance for LB2501, a first-of-its-kind in vivo CD19/CD20 dual-targeting CAR-T, enabling a planned U.S. Phase 1/2 study in relapsed or refractory B-cell malignancies.
Key Events · Product Development and Regulatory · LEGN
-
FDA Clears LB2501 IND
FDA cleared the IND for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T for relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma.
-
First Dual-Targeting In Vivo CAR-T
Legend states LB2501 is the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance, built on its proprietary TaVec lentiviral vector platform.
-
U.S. Phase 1/2 Study Planned
The clearance supports a planned U.S. Phase 1/2 trial evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy; an ongoing Phase 1 study in China (NCT07002112) is the only human data cited.
-
Differentiated Dosing Approach
LB2501 is designed as an off-the-shelf single infusion that generates CAR-T cells in vivo and is being evaluated without lymphodepleting chemotherapy, potentially avoiding manufacturing steps of conventional autologous CAR-T.
Analysis · LEGN · Life Sciences
FDA clearance of the LB2501 IND opens the door to a U.S. Phase 1/2 study of an off-the-shelf in vivo CAR-T that generates CD19/CD20 dual-targeting cells inside the patient after a single infusion, without lymphodepleting chemotherapy. It is the first known dual-targeting in vivo CAR-T to clear an IND, extending Legend's pipeline beyond CARVYKTI into a next-generation platform. This is early-stage: no efficacy or safety data from the U.S. study yet, and the ongoing China Phase 1 (NCT07002112) is the only human experience cited. The value is strategic optionality, not near-term revenue.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.4% of the 1987 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $19.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $16.24 to $37.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.